Novo Holder Boosts Investments With $7 Billion Goal, FT Reports

Novo Nordisk A/S’s largest shareholder plans to invest as much as $7 billion a year by 2030, buoyed by the success of the Danish drugmaker’s blockbusters for obesity and diabetes, the Financial Times reported.

Novo Holdings, which controls 77% of the votes in Europe’s most valuable company, expects the rising income to allow it to invest $5 billion annually in the next five years and $7 billion thereafter, the FT said, citing an interview with CEO Kasim Kutay.